Musgrave Ian F, Van Der Zypp Andrea, Grigg Mathew, Barrow Colin J
Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia.
Ann N Y Acad Sci. 2003 Dec;1009:222-7. doi: 10.1196/annals.1304.027.
Agmatine and harmane have been proposed as endogenous ligands of imidazoline receptors. Agmatine has been reported to activate nitric oxide synthetase (NOS) in endothelial cells, so we sought to determine if agmatine or harmane and an analogue of harmane, propyl harmane, produced vasodilatation through an endothelium-dependent mechanism. The experiments were performed in endothelium-denuded and intact rat aortic rings preconstricted with phenylephrine (0.1 microM). Agmatine (0.3-1000 microM), harmane, and propyl harmane (0.3-100 microM) relaxed endothelium-intact rings in a concentration-dependent manner. Removal of endothelium inhibited the relaxant effect of agmatine, harmane, and propyl harmane. The NOS inhibitor L-NIO (100 microM) inhibited the relaxant effect of agmatine and harmane. The I(1)-receptor antagonist AGN (100 microM) partly inhibited the effect of harmane but not that of agmatine. These results suggest that the endogenous imidazoline ligands are capable of stimulating NOS largely by an I(1)-receptor-independent mechanism.
胍丁胺和哈尔满被认为是咪唑啉受体的内源性配体。据报道,胍丁胺可激活内皮细胞中的一氧化氮合酶(NOS),因此我们试图确定胍丁胺、哈尔满或哈尔满的类似物丙基哈尔满是否通过内皮依赖性机制产生血管舒张作用。实验在预先用去氧肾上腺素(0.1微摩尔)预收缩的去内皮和完整大鼠主动脉环中进行。胍丁胺(0.3 - 1000微摩尔)、哈尔满和丙基哈尔满(0.3 - 100微摩尔)以浓度依赖性方式使完整内皮环舒张。去除内皮可抑制胍丁胺、哈尔满和丙基哈尔满的舒张作用。NOS抑制剂L - NIO(100微摩尔)可抑制胍丁胺和哈尔满的舒张作用。I(1)受体拮抗剂AGN(100微摩尔)部分抑制哈尔满的作用,但不抑制胍丁胺的作用。这些结果表明,内源性咪唑啉配体能够主要通过不依赖I(1)受体的机制刺激NOS。